Observational studyKorean journal of ophthalmology : KJO2025
Ten-Year Trends of Intravitreal Injection in South Korea Using the Health Insurance Review and Assessment Service Data.
Observational study in Korean journal of ophthalmology : KJO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeThis study aims to analyze the annual trends of intravitreal injection (IVI) in South Korea.
methodsThis retrospective study examined data from the Health Insurance Review and Assessment Service (HIRA)'s Health and Medical Big Data Open Portal. We investigated the number of patients who underwent IVIs and the total number of IVIs in Korea using the procedure code from 2014 to 2023, categorized by age group and type of healthcare facility. Patients aged under 40 years were excluded from the analysis. Additionally, trends in healthcare expenditures were analyzed.
resultsThe number of patients undergoing IVI and the total number of IVI increased steadily, resulting in 92,124 patients (178.1 patients per 100,000 persons) and 291,784 injections in 2023, which contributed to an increase in medical expenses. The analysis of 10-year age intervals revealed that patients in their 70s were the most frequent recipients of IVI. The prevalence of IVI at primary healthcare facilities has been steadily increasing, from 20% in 2014 to 33% in 2023.
conclusionsThe patients receiving IVI and the total number of IVI have been steadily increasing, particularly in primary healthcare settings. Overall, medical expenses continue to rise. The findings of this study provide valuable evidence for the efficient allocation of medical resources in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.